Program directory
Off-Label Longevity Prescribing: Compare Costs, Monitoring, and Unknowns
Compare what common off-label longevity drugs are approved to treat, what current programs charge, what should be monitored, and what human research has not proved. The useful question is not whether a drug affects an aging process; it is whether benefits outweigh risks for you.
Prescription Comparison
Approved Drug Does Not Mean Approved Longevity Use
Starting prices are current public examples checked on October 11, 2026. They may not include laboratory work, clinician visits, shipping, dose changes, or treatment of side effects.
| Drug or class | Approved use | Longevity claim | Current public price example | Monitoring to discuss | What remains unknown |
|---|---|---|---|---|---|
| Rapamycin or sirolimus | Prevention of kidney-transplant rejection and treatment of lymphangioleiomyomatosis for the branded sirolimus label reviewed here. | Intermittent low dosing is sold as a way to reduce mTOR signaling and support healthier aging. | AgelessRx lists rapamycin starting at $65 per month. | Medication interactions, infection risk, mouth ulcers, lipids, blood counts, kidney and liver measures, wound healing, and plans around surgery or illness. | The 48-week PEARL trial missed its primary visceral-fat endpoint. Some secondary signals appeared, but no human trial has shown longer life from this use. |
| Metformin | Improved glucose control in type 2 diabetes alongside diet and exercise. | Metabolic and observational findings are used to suggest slower aging in people without diabetes. | AgelessRx lists metformin starting at $25 per month. | Kidney function, vitamin B12 over time, stomach effects, other glucose-lowering drugs, heavy alcohol use, and temporary holds around some contrast studies or acute illness. | Human trials have not established that prescribing metformin to a healthy person extends life or prevents the major diseases of aging. |
| GLP-1 or GIP and GLP-1 drug | Specific products are approved for type 2 diabetes, chronic weight management, and selected cardiovascular or sleep-apnea risk reduction uses. | Benefits seen in people with obesity or diabetes are sometimes presented as a general longevity treatment or sold in very low doses. | AgelessRx lists microdosing tirzepatide starting at $109 per month. Product, dose, and pharmacy can change the total. | Weight trend, nutrition, muscle preservation, stomach effects, gallbladder symptoms, pancreatitis warnings, and the reason for continuing. | Outcome evidence from people with an approved indication does not prove a longevity benefit for a healthy-weight person using an untested dose. |
| Acarbose | Improved glucose control in adults with type 2 diabetes alongside diet and exercise. | Animal longevity results and control of after-meal glucose are used to support off-label use in people without diabetes. | Many longevity sellers do not publish a standalone price. Ask for the drug, visit, and lab costs separately. | Digestive effects, liver tests when appropriate, glucose-lowering combinations, bowel conditions, and whether the expected glucose change occurs. | There is no completed human trial showing that acarbose extends life in healthy adults. |
| Focus | Prescription model |
|---|---|
| What It Covers |
|
| Typical Cost | Current public starting examples are $25 per month for metformin, $65 per month for rapamycin, and $109 per month for microdosing tirzepatide before possible labs, visits, dose changes, or shipping |
| Evidence Level | Early for use against aging: the PEARL rapamycin trial missed its primary endpoint and reported limited secondary signals, metformin geroprotection remains under study, and GLP-1 outcome evidence applies to defined medical indications rather than general treatment of aging |
| Regulatory Status | FDA-approved drugs prescribed off-label; no drug is approved to treat aging |
| Watchouts |
|
| Questions To Ask |
|
Sources
Current Evidence and Published Prices
Prices and program terms can change. The check date shows when each public source was reviewed.
- DailyMed sirolimus prescribing information Lists approved uses, boxed warnings, monitoring, interactions, and major precautions for Rapamune. Checked 2026-10-11
- PEARL randomized rapamycin trial Reports 48-week safety and healthspan results, including the unchanged primary visceral-adiposity endpoint and limited secondary signals. Checked 2026-10-11
- DailyMed metformin prescribing information Lists the type 2 diabetes indication, kidney guidance, dosing, and major precautions. Checked 2026-10-11
- ClinicalTrials.gov metformin geroprotection study Shows that human geroprotection research remains an active study question rather than an established indication. Checked 2026-10-11
- DailyMed acarbose prescribing information Lists the type 2 diabetes indication, contraindications, and monitoring concerns. Checked 2026-10-11
- DailyMed Zepbound prescribing information Lists approved tirzepatide uses for chronic weight management and obstructive sleep apnea in defined populations, plus dosing and warnings. Checked 2026-10-11
- AgelessRx longevity treatments and starting prices Lists current starting prices for metformin, rapamycin, and microdosing tirzepatide. Checked 2026-10-11
Parallel Coverage
Related Resources
This profile connects back into the article, glossary, and FAQ layers so overlapping coverage stays discoverable instead of fragmented.
Article
What Is Longevity Medicine?
How longevity medicine differs from conventional healthcare, what it typically involves, and where the evidence stands.
ArticleThe Hallmarks of Aging
A guide to the biological processes researchers believe drive aging at the cellular level, and why they matter for longevity science.
ArticleFasting and Longevity Research
What research on caloric restriction, time-restricted eating, and intermittent fasting actually shows about healthspan.